Cassava Sciences announced the termination of its advanced trial for simufilam, an Alzheimer’s drug, due to its inability to significantly reduce cognitive decline in patients.
The disappointing trial results were a setback for patients and their families, who had been hoping for a new treatment option amid ongoing struggles with Alzheimer’s disease.
Many dementia researchers were not surprised by the trial's outcome, as concerns surrounding the scientific integrity of the drug had been raised prior to the study.
After the failed trial, Cassava's future is uncertain as simufilam was the only drug in development, with the company facing prior allegations of misleading statements.
Collection
[
|
...
]